Skip Navigation

European Journal of Heart Failure 2009 11(10):967-972; doi:10.1093/eurjhf/hfp125
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Parissis, J. T.
Right arrow Articles by Kremastinos, D. Th.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parissis, J. T.
Right arrow Articles by Kremastinos, D. Th.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study

John T. Parissis*, Dimitrios Farmakis, Maria Nikolaou, Dionysia Birmpa, Vassiliki Bistola, Ioannis Paraskevaidis, Ignatios Ikonomidis, Stavroula Gaitani, Koula Venetsanou, Gerasimos Filippatos and Dimitrios Th. Kremastinos

Second Department of Cardiology, Heart Failure Clinic, Attikon University Hospital, 13 Navarinou Street, 15122 Maroussi, Athens, Greece

* Corresponding author. Tel: +30 210 6123720, Fax: +30 210 5832351, Email: jparissis{at}yahoo.com


   Abstract

Aims: To assess the prognostic value of a wide spectrum of neurohormonal and inflammatory markers along with functional status and exercise capacity, in hospitalized chronic heart failure (CHF) patients with depressive symptoms.

Methods and results: A total of 300 consecutive hospitalized CHF patients were screened for depressive symptomatology using the Zung self-rated depression scale (SDS). Patients with depressive symptoms (Zung SDS ≥40) underwent a 6 min walking test, and evaluation of left ventricular ejection fraction, B-type natriuretic peptide (BNP), and plasma inflammatory/anti-inflammatory factors [interleukin (IL)-6, IL-10, tumour necrosis factor-{alpha}, soluble intercellular adhesion molecule-1, and vascular cell adhesion molecule-1]. Patients were subsequently followed for up to 1 year for major adverse cardiovascular events (MACE, death or hospitalization due to cardiovascular causes). One hundred and fourteen patients (38%) had a Zung SDS ≥40. One-year event-free survival of these patients was 19% (mean ± SE, 150 ± 12 days). In multivariate analysis, only BNP (HR = 1.001, P = 0.002) and IL-10 (HR = 0.864, P = 0.049) were independent predictors of MACE. Using receiver operator characteristics analysis-derived cut-offs, a BNP value of 290 pg/mL predicted MACE with 86% sensitivity and 69% specificity, whereas an IL-10 value of 5 pg/mL predicted MACE with 61% sensitivity and 78% specificity. Event-free survival differed significantly between patients with BNP < 290 pg/mL and IL-10 > 5 pg/mL (261 ± 44 days) and those with BNP > 290 pg/mL and IL-10 < 5 pg/mL (79 ± 11 days, P = 0.0001).

Conclusion: Neurohormonal activation and defective anti-inflammatory properties are independent predictors of long-term outcome in hospitalized CHF patients with depressive symptoms.

Key Words: Depression • Heart failure • Inflammation • Biomarkers • Prognosis

Received May 14, 2009; Revised July 28, 2009; Accepted August 18, 2009


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.